<SEC-DOCUMENT>0001213900-20-001288.txt : 20200117
<SEC-HEADER>0001213900-20-001288.hdr.sgml : 20200117
<ACCEPTANCE-DATETIME>20200117161741
ACCESSION NUMBER:		0001213900-20-001288
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200117
DATE AS OF CHANGE:		20200117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-235695
		FILM NUMBER:		20533776

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>f424b3011720_aytu.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT NO. 1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Prospectus Supplement No. 1</B></P>

<P STYLE="margin: 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="margin: 0; text-align: right"><B>File No. 333-235695</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="aytulogo.jpg" ALT=""></TD>
    <TD STYLE="width: 50%; text-align: right"><IMG SRC="innovuslogo.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Prospectus Supplement No. 1 Dated January 17,
2020</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">To Prospectus Dated January 15, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 8pt; margin-right: 0; margin-left: 0; text-indent: 0.5in">This prospectus supplement corrects and
clarifies the calculation of the maximum shares to be issued or become issuable to Innovus stockholders in relation to the Merger,
as defined and discussed in the joint proxy statement/prospectus dated January 15, 2020 (the &ldquo;Prospectus&rdquo;). The Prospectus
states that, if the Merger is completed, the total number of shares of Aytu common stock to be issued to Innovus stockholders
at closing is determined pursuant to a formula set forth in Section 2.01(b)(i) of the merger agreement that takes into account
the amount of additional debt incurred by Innovus Pharmaceuticals, Inc, (&ldquo;Innovus&rdquo;) since the date of signing and
the impact of certain other components that are said to not be currently calculable. On page 179 in the section titled &ldquo;Merger
Agreement&mdash;Merger Consideration&rdquo;, the Prospectus describes this formula in more detail, and when describing the deduction
relating to payouts to holders of Innovus warrants with cash-out rights, it incorrectly states that while this component is not
currently calculable it is not expected to result in a deduction to the number of shares of Aytu common stock to be issued at
closing. In fact, it is expected that this deduction (assuming the Aytu and Innovus&rsquo; share prices do not change significantly
between now and closing) would be approximately $0.3 million, and so this part of the Prospectus should instead read:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting Consideration Value</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$8,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deduction for Promissory Note owed by Innovus to Aytu</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,350,000</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deduction for value of payouts to holders of Innovus warrants with cash-out rights (including those who elect to take Series H shares) to the extent such value is greater than $1,300,000</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not currently calculable but based on today&rsquo;s trading prices for Aytu and Innovus&rsquo; common stock, this deduction would be approximately $0.3 million.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deduction for increases to long-term liabilities between June 30, 2019 and closing</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not currently calculable, but no material increases as at January 15, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deduction for reductions in net working capital between June 30, 2019 and closing</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not currently calculable, but no material reduction as at January 15, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending Consideration Value (to the extent currently calculable)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.4 million</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Maximum Number of shares to be issued (Ending Consideration Value divided by $1.69)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,780,000</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In several places, including those referenced
below, the Prospectus also states that we do not expect the total number of shares of Aytu BioScience, Inc. (&ldquo;Aytu&rdquo;)
common stock to be issued as merger consideration at the time of the merger to exceed approximately 3.9 million. As a result of
the deduction component described above, and based on our calculations, we do not expect the total number of shares of Aytu common
stock to be issued as merger consideration at the time of the merger to exceed approximately 3.78 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Sections where 3.9 million is referenced as
the maximum number of shares of Aytu common stock to be issued as merger consideration at the time of the closing, which instead
should state 3.78 million:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt; text-transform: uppercase">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="width: 84%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Merger Proposal &ndash; Your Vote is Very Important </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<B>Page 2 of the Letter</B>)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt; text-transform: uppercase">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">QUESTIONS AND ANSWERS ABOUT THE MERGER AND THE SPECIAL MEETINGS (<B>P</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">age 6</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY (<B>Page 24)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS &ndash; RISKS &ndash; RISKS RELATED TO THE MERGER (<B>Page 31 - 32)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS &ndash; RISKS &ndash; RISKS RELATED TO OUR ORGANIZATION, STRUCTURE AND OPERATION (<B>Page 61</B>)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE 2, NOTE 3, AND NOTE 4 TO THE <FONT STYLE="text-transform: uppercase">CERTAIN UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS (<B>P</B></FONT><B>ages 85 -93</B>)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INNOVUS PROPOSAL I: ADOPTION OF THE MERGER AGREEMENT AND AYTU PROPOSAL I: APPROVAL OF THE MERGER CONSIDERATION (<B>Page 154</B>)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE MERGER AGREEMENT (<B>Page 179</B>)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERESTS OF AYTU&rsquo;S DIRECTORS AND EXECUTIVE OFFICERS IN THE MERGER (<B>Page 203</B>)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-indent: 0.5in">In addition, we anticipate that due to
the above, Aytu stockholders are expected to own approximately 84.5% of the outstanding shares of Aytu common stock and former
Innovus stockholders are expected to own approximately 15.5% of outstanding common stock (without consideration of the shares of
Aytu common stock underlying the CVRs, common stock underlying the Aytu Series H convertible preferred stock to be offered in exchange
for certain Innovus warrants, and common stock to be issued to certain employees of Innovus immediately post-merger under the Aytu
Incentive Plan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 0.5in">In addition, we anticipate that due to
the above, Armistice Capital, LLC (&ldquo;Armistice&rdquo;) is expected to receive a maximum of 270,000 shares of Aytu common stock
(not including shares of Aytu common stock underlying CVRs and any shares of Series H convertible preferred stock in the event
Armistice elects to exchange certain outstanding Innovus warrants with cash-out rights for shares of such Series H convertible
preferred stock prior to the closing of the merger).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 0.5in">In addition, we anticipate that due to
the above (without considering any potential CVR payout or shares of Series H convertible preferred stock in the event Armistice
elects to exchange certain outstanding Innovus warrants wth cash-out rights), Armistice is expected to beneficially own a maximum
of approximately 21.78 million shares of Aytu common stock, including 13,637,796 shares of common stock underlying Armistice owned
preferred stock/warrants, representing approximately 57.1% of the shares of Aytu common stock expected to be outstanding after
the merger, including shares beneficially owned by Armistice. Armistice is, and after the merger will continue to be, the largest
stockholder of Aytu and will be able to exercise control over Aytu. Armistice may use such control to influence Aytu after the
merger in ways that could negatively affect Aytu&rsquo;s operations and financial results. <I>Notwithstanding the above, Armistice
is restricted from holding at any given time greater than 40.0% of the outstanding Aytu common stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-indent: 0.5in">In addition, we anticipate that due to
the above, sections where we reported the merger consideration represented approximately $0.98 in value per share of Innovus common
stock, should instead indicate $0.91 (without considering any potential CVR payout or any deductions from the merger consideration
provided for in the merger agreement). The following sections were impacted by this:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0 1in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
MERGER PROPOSAL &mdash; YOUR VOTE IS VERY IMPORTANT (<B>Page 1</B>)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0 1in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
QUESTIONS AND ANSWERS ABOUT THE MERGER AND THE SPECIAL MEETINGS (<B>Page 4</B>)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This prospectus supplement should be read in
conjunction with the Prospectus, and this prospectus supplement is qualified in its entirety by reference to the Prospectus, except
to the extent that the information herein modifies or supersedes the information contained in the Prospectus. Except as specifically
corrected by this prospectus supplement, the &ldquo;About This Joint Proxy Statement/Prospectus&rdquo; section of the Prospectus
is not affected by this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Before voting, whether you are an Aytu stockholder
or an Innovus stockholder, you should carefully review all the information contained in this prospectus supplement and the Prospectus,
including its annexes and information incorporated by reference. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED
UNDER &ldquo;RISK FACTORS&rdquo; BEGINNING ON PAGE 26 OF THE PROSPECTUS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of the securities to be issued in connection with the transaction
described in the Prospectus or determined whether the Prospectus is truthful or complete. Any representation to the contrary is
a criminal offense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This date of this prospectus supplement is January
17, 2020 and this prospectus supplement is first being mailed to the Aytu stockholders and Innovus stockholders on or around January
21, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>aytulogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aytulogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- /(# 2(  A$! Q$!_\0
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M:UL5Y/X?^-/@;3_#>E6=QJDJSV]G#%(HM93AE0 C.WU%:/\ PO3P!_T%IO\
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M3K.PLH+.VMHX[>"-8HD X55& /R%%6J* "BBB@ HHHH **** "BBB@ HHHH
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G'##.!QVI@=3:RM/:0S/&8WDC5F0C!4D9Q14JY"C<<G')QUHI ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>innovuslogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 innovuslogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M -,# 2(  A$! Q$!_\0
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M"_C7,MN3_P"/+ZK_ "[]L[8G!2HKF3NOR,,-CHUGRM6?YG2T5P/Q< /A>R!
M(^WKU_ZYR5M> ACP-I8''[ML?]]-6+HVHJK?=V-U6O6=*VRN3>*/$5CH6GLD
M^HQ65W<1NMJ[QM( ^.&(4'@$C/:J-[>>(+?3M,\J9;J1X09KBUA#+*_'08.
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MP/;V]:*TEC\-=^Y?Y(SC@,39>_;YLZRBBBO&/:"BBB@ HHHH **** "BBB@
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F$U2\59#M6>0#=ECC<>I)R?J:*\V688M-K3[D>G'+L)))Z_>S_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
